Smiths Detection Announces University of Maryland, Baltimore County Successfully Deploys BioFlash for Airborne Detection of SARS-CoV-2
Smiths Detection, a global leader in threat detection and security screening technologies, today announces that its BioFlash® Biological Identifier has been successfully used by the University of Maryland, Baltimore County (UMBC) to identify airborne SARS-CoV-2 inside their campus in real-time at the point of testing.
As part of their mitigation strategy for COVID-19, UMBC’s Environmental Safety and Health (ESH) team have been using BioFlash across the campus. In one instance, the airborne detector was deployed to help the campus community safely re-enter a research facility after a person working there tested positive. After multiple tests performed on the BioFlash ruled-out the presence of airborne SARS-CoV-2, the ESH team deemed the facility contamination-free, allowing staff and students to safely return and research to continue without significant pause.
In a separate instance, in a collaborative effort with the UMBC Sports Medicine Department, a test conducted in a team locker room resulted in a positive environmental detection on the BioFlash. This detection ultimately led UMBC to test all people present for COVID-19, identifying three infected individuals. This helped prevent further spread of the virus.
“We are delighted to see what we believe is a world-first for our technology. BioFlash, with its real-time results capability, has been used by UMBC in a real-world setting to successfully confirm the presence or absence of COVID-19 in the air and inform health and safety protocols,” said Smiths Detection President Roland Carter. “We have been working incredibly hard to provide a tool that will support the ongoing fight against COVID-19, and these applications demonstrate the role BioFlash can play in virus mitigation strategies.”
“The BioFlash system has helped us to prevent the spread of the virus in our on-campus community. We are also pleased that this tool to protect the health and safety of people on our campus is easy to use and environmentally friendly,” said Lynne Schaefer, UMBC Vice President for Administration and Finance. “We will be using this solution as part of a larger mitigation strategy, alongside other important tools like sanitation, masks, regular testing, physical distancing, and symptom monitoring.”
BioFlash works by collecting and analysing air samples using sensitive, selective and rapid detection technology to identify the presence of dangerous pathogens onsite without the need to involve a laboratory. Following successful internal testing, Smiths Detection has been engaged in various external studies to further verify the SARS-CoV-2 detection capability, including working with the USAMRIID, which verified that BioFlash could identify SARS-CoV-2 in a laboratory setting.
The BioFlash Biological Identifier is available now.
ENDS
About BioFlash Biological Identifier
The BioFlash® Biological Identifier is a bio-aerosol collection and identification system that provides rapid, sensitive and specific identification of various pathogens including viruses, toxins and bacteria. The BioFlash has been commercially available for over 10 years and is currently used by US government and commercial clients for a number of applications.
About Smiths Detection
Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, defence and urban security markets. Our experience and history across more than 40 years at the frontline enables us to deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
For more information visit http://www.smithsdetection.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005091/en/
Contact information
FTI Consulting:
Tom Hufton/Georgina Reeves
sc.smithsdetection@fticonsulting.com
+44 (0)20 3727 1000
Smiths Detection:
Sophie Mills
Communications Manager
sophie.mills@smithsdetection.com
+ 44 (0)7384236474
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Latest Cloud Survey From Denodo Reveals Advanced Workloads Moving to the Cloud While Hybrid and Multi-Cloud Management Skills Are in High Demand18.5.2021 10:00:00 EEST | Press release
Data virtualization leader Denodo’s fourth annual cloud usage survey finds organizations are accelerating their cloud journey to take advantage of its flexibility, control costs, speed time-to-market, and simplify data management. According to survey respondents, which included 150 global business and IT professionals from various industry sectors, hybrid-cloud deployment remains the dominant choice, as more than a third of these organizations (35 percent) use this model. Private cloud has shown some vibrant usage, accounting for almost a quarter of all workloads (24 percent), followed by public cloud, which remained almost flat at 16 percent. Multi-cloud remains a popular choice for almost one in ten organizations (9 percent) who opt to procure best of breed applications, data repositories, and infrastructure orchestration technologies among different cloud service providers to avoid a single vendor lock-in. This press release features multimedia. View the full release here: https://w
Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)18.5.2021 09:39:00 EEST | Press release
Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralising potency against emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and India (B.1.617).1 The Korea Disease Control and Prevention Agency (KDCA) has assessed the test by combining the antibody with recent emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and Brazil (P.1); infecting the host cell with this combination to identify neutralising effect against the variants with CT-P59. The monoclonal antibody candidate CT-P59 demonstrated strong neutralising capability against the New York (B.1.526) and Nigeria (B.1.525) variants and produced neutralising titers against the Indian variant (B.1.617) in an in-vitro pseudo virus assay.1 The company plans to study neutralising titers against additional emerging strains, including the Brazil variant (P.1)2, in order to proactively address the pandemic as the virus con
iBASIS Carrier Voice for Teamwork™ Enables China Telecom Europe (CTE) and the Carrier Community to Meet Surging Post-Pandemic Enterprise Demand18.5.2021 08:00:00 EEST | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, today announced the launch of iBASIS Carrier Voice for Teamwork, enabling carriers such as China Telecom Europe (CTE), a leading provider to European multinationals, to serve Enterprise customers with much needed cloud-based PBX functionality for their collaboration platforms. With the massive shift toward Microsoft Teams triggered by COVID-19, carriers have an immediate opportunity to seize new Enterprise revenues by delivering a proven solution to bring voice to Microsoft Teams. iBASIS Carrier Voice for Teamwork™ provides global service availability, from and to the cloud via 2-way PSTN numbers, enabling native voice service in 60+ markets for global termination to help carriers respond to their local Enterprise demand. Carriers have the option to keep their own numbers to avoid porting or leverage iBASIS for local numbers. The solution is built on iBASIS’ established wholesale leade
Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine Candidate18.5.2021 08:00:00 EEST | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago’s plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and reiterate the promising profile observed during Phase 1 testing. Immunogenicity, as measured by the neutralizing antibody titer, was high - about 10 times higher than those in a panel of sera from patients recovering from COVID-19. No related severe adverse events were reported and reactogenicity was generally mild to moderate and short in duration. “We are very excited to see such positive results from the Phase 2 data. After two doses, the adjuvanted vaccine candidate induced robust neutralizing antibody and cellular immune responses in all subjects, irrespectively of age,” said Nathalie Landry, Executive Vice President,
Stephen Stonberg appointed interim CEO of Bittrex Global17.5.2021 20:14:00 EEST | Press release
The Boards of Directors (the “Boards”) of Bittrex Global GmbH (Vaduz, Liechtenstein) and Bittrex Global (Bermuda) Ltd (Hamilton, Bermuda) have confirmed that Tom Albright is stepping down from his role as CEO of both companies effective today. The Boards are grateful for the contributions Tom has made. Stephen Stonberg, current CFO and COO of Bittrex Global, has been appointed by the Boards to serve as interim CEO, to oversee management of the Companies. “Tom has brought key leadership as Bittrex Global has grown to serve the crypto marketplace,” said Bill Shihara, Co-Founder Bittrex, Inc. “Tom has also helped guide the company through a period of significant growth and change within our sector”. “We are incredibly pleased that Stephen Stonberg will be leading Bittrex Global as interim CEO,” said Shihara. “Stephen has served as CFO and COO since February 2019, and has a deep understanding of our business, and has over 25 years experience in the financial services sector, and held leade
Lumen Metabolic Health Device Now Peer-reviewed17.5.2021 19:57:00 EEST | Press release
Lumen , a health tech company and the creators of the world's first portable metabolism measurement device, has officially been peer-reviewed and published in the Interactive Journal of Medical Research (I-JMR). In collaboration with San Francisco State University, Lumen has validated an ongoing study launched in 2020, which shows the validity of Lumen® to detect changes in metabolic fuel utilization in a comparable manner with a laboratory standard metabolic cart, providing the ability for real-time metabolic information for users under any circumstances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005774/en/ Lumen now peer-reviewed (Photo: Business Wire) Developed through years of scientific testing and validation, Lumen is the first handheld, portable device and app that measures your metabolism in real-time with just your breath. The methodology behind the peer-reviewed validation of Lumen The study compares the
Orbia Announces Cash Tender Offer for Its Outstanding Notes Due 202217.5.2021 16:46:00 EEST | Press release
Orbia Advance Corporation, S.A.B. de C.V. (“Orbia”) (BMV: ORBIA) announces that it has commenced an offer to purchase its outstanding US$750,000,000 principal amount of 4.875% Senior Notes due 2022 (CUSIP/ISIN: 59284BAB4; P57908AD0 / US59284BAB45; USP57908AD01) (the “Securities”) pursuant to an offer (the “Tender Offer”) to purchase for cash any and all of the Securities on the terms and subject to the conditions set forth in the offer to purchase, dated May 17, 2021 (the “Offer to Purchase”) and the related notice of guaranteed delivery (the “Notice of Guaranteed Delivery” and, together with the Offer to Purchase, the “Offer Documents”). The Tender Offer will expire at 5:00 p.m. (New York City time) on May 21, 2021, unless extended (such date and time, as the same may be extended, the “Expiration Date”). Securities validly tendered may be withdrawn at any time at or prior to 5:00 p.m. (New York City time) on May 21, 2021, unless extended, but not thereafter. The settlement date of the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom